ECSP17015977A - Terapia de combinacion - Google Patents
Terapia de combinacionInfo
- Publication number
- ECSP17015977A ECSP17015977A ECIEPI201715977A ECPI201715977A ECSP17015977A EC SP17015977 A ECSP17015977 A EC SP17015977A EC IEPI201715977 A ECIEPI201715977 A EC IEPI201715977A EC PI201715977 A ECPI201715977 A EC PI201715977A EC SP17015977 A ECSP17015977 A EC SP17015977A
- Authority
- EC
- Ecuador
- Prior art keywords
- combination therapy
- therapy
- combination
- attached
- summary attached
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Massaging Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE ADJUNTA RESUMEN
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050967P | 2014-09-16 | 2014-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17015977A true ECSP17015977A (es) | 2018-03-31 |
Family
ID=54207720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201715977A ECSP17015977A (es) | 2014-09-16 | 2017-03-15 | Terapia de combinacion |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9999624B2 (es) |
| EP (1) | EP3193882A1 (es) |
| JP (1) | JP6339741B2 (es) |
| KR (1) | KR101871128B1 (es) |
| CN (1) | CN106687136A (es) |
| AP (1) | AP2017009794A0 (es) |
| AR (1) | AR101740A1 (es) |
| AU (1) | AU2015318257B2 (es) |
| BR (1) | BR112017003571A2 (es) |
| CA (1) | CA2956835A1 (es) |
| CL (1) | CL2017000558A1 (es) |
| CO (1) | CO2017001875A2 (es) |
| CR (1) | CR20170080A (es) |
| DO (1) | DOP2017000071A (es) |
| EA (1) | EA031764B1 (es) |
| EC (1) | ECSP17015977A (es) |
| IL (1) | IL250387A0 (es) |
| MX (1) | MX2017003414A (es) |
| NZ (1) | NZ728636A (es) |
| PE (1) | PE20170464A1 (es) |
| PH (1) | PH12017500493A1 (es) |
| SG (1) | SG11201701330PA (es) |
| SV (1) | SV2017005389A (es) |
| TN (1) | TN2017000072A1 (es) |
| TW (1) | TWI599358B (es) |
| WO (1) | WO2016043997A1 (es) |
| ZA (1) | ZA201700826B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107893A1 (es) * | 2016-03-15 | 2018-06-28 | Astrazeneca Ab | TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JP2019530647A (ja) | 2016-08-18 | 2019-10-24 | イーライ リリー アンド カンパニー | Ｂａｃｅ−１阻害剤と抗ｎ３ｐｇｌｕ ａベータ抗体の併用療法 |
| TWI669119B (zh) * | 2016-10-21 | 2019-08-21 | 美國禮來大藥廠 | 組合療法 |
| BR112018013084A2 (pt) | 2016-10-28 | 2018-12-11 | H Lundbeck As | tratamentos de combinação compreendendo a administração de imidazopirazinonas |
| TWI705975B (zh) * | 2017-04-20 | 2020-10-01 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| LT3723807T (lt) | 2017-12-14 | 2021-12-10 | H. Lundbeck A/S | Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
| US12350278B2 (en) | 2018-06-27 | 2025-07-08 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections in non-human animals |
| US10350226B1 (en) | 2018-06-27 | 2019-07-16 | Joshua O. Atiba | Therapy and prevention of prion protein complex infections |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| US20230236199A1 (en) * | 2020-04-23 | 2023-07-27 | Eli Lilly And Company | Subcutaneous absorption and bioavailability of antibodies |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| CN119497721A (zh) | 2022-07-29 | 2025-02-21 | 艾莱克特有限责任公司 | 转铁蛋白受体抗原结合结构域及其用途 |
| JP2025528751A (ja) | 2022-07-29 | 2025-09-02 | アレクトル エルエルシー | Ｃｄ９８ｈｃ抗原結合ドメイン及びその使用法 |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1660443B1 (en) | 2003-08-08 | 2009-03-04 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| ES2548774T3 (es) * | 2008-01-18 | 2015-10-20 | Eisai R&D Management Co., Ltd. | Derivado de aminodihidrotiazina condensado |
| DK3339323T3 (da) * | 2010-08-12 | 2020-01-20 | Lilly Co Eli | Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf |
| GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
| TWI593692B (zh) * | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
-
2015
- 2015-09-01 TW TW104128851A patent/TWI599358B/zh not_active IP Right Cessation
- 2015-09-02 AR ARP150102803A patent/AR101740A1/es unknown
- 2015-09-08 CA CA2956835A patent/CA2956835A1/en not_active Abandoned
- 2015-09-08 NZ NZ728636A patent/NZ728636A/en not_active IP Right Cessation
- 2015-09-08 US US15/503,027 patent/US9999624B2/en not_active Expired - Fee Related
- 2015-09-08 AU AU2015318257A patent/AU2015318257B2/en not_active Ceased
- 2015-09-08 TN TN2017000072A patent/TN2017000072A1/en unknown
- 2015-09-08 WO PCT/US2015/048807 patent/WO2016043997A1/en not_active Ceased
- 2015-09-08 CN CN201580049574.0A patent/CN106687136A/zh active Pending
- 2015-09-08 AP AP2017009794A patent/AP2017009794A0/en unknown
- 2015-09-08 JP JP2017514623A patent/JP6339741B2/ja not_active Expired - Fee Related
- 2015-09-08 CR CR20170080A patent/CR20170080A/es unknown
- 2015-09-08 EP EP15771800.8A patent/EP3193882A1/en not_active Withdrawn
- 2015-09-08 SG SG11201701330PA patent/SG11201701330PA/en unknown
- 2015-09-08 KR KR1020177006748A patent/KR101871128B1/ko not_active Expired - Fee Related
- 2015-09-08 MX MX2017003414A patent/MX2017003414A/es unknown
- 2015-09-08 EA EA201790305A patent/EA031764B1/ru not_active IP Right Cessation
- 2015-09-08 BR BR112017003571A patent/BR112017003571A2/pt not_active Application Discontinuation
- 2015-09-08 PE PE2017000406A patent/PE20170464A1/es unknown
-
2017
- 2017-02-01 IL IL250387A patent/IL250387A0/en unknown
- 2017-02-02 ZA ZA2017/00826A patent/ZA201700826B/en unknown
- 2017-02-22 SV SV2017005389A patent/SV2017005389A/es unknown
- 2017-02-24 CO CONC2017/0001875A patent/CO2017001875A2/es unknown
- 2017-03-08 CL CL2017000558A patent/CL2017000558A1/es unknown
- 2017-03-14 DO DO2017000071A patent/DOP2017000071A/es unknown
- 2017-03-15 PH PH12017500493A patent/PH12017500493A1/en unknown
- 2017-03-15 EC ECIEPI201715977A patent/ECSP17015977A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2017000072A1 (en) | 2018-07-04 |
| JP2017529348A (ja) | 2017-10-05 |
| US9999624B2 (en) | 2018-06-19 |
| ZA201700826B (en) | 2018-12-19 |
| IL250387A0 (en) | 2017-03-30 |
| AU2015318257B2 (en) | 2018-06-14 |
| CR20170080A (es) | 2017-03-30 |
| CO2017001875A2 (es) | 2017-05-19 |
| EA031764B1 (ru) | 2019-02-28 |
| JP6339741B2 (ja) | 2018-06-06 |
| SV2017005389A (es) | 2018-01-17 |
| PE20170464A1 (es) | 2017-04-26 |
| WO2016043997A1 (en) | 2016-03-24 |
| TW201618786A (zh) | 2016-06-01 |
| US20170224702A1 (en) | 2017-08-10 |
| AP2017009794A0 (en) | 2017-03-31 |
| PH12017500493A1 (en) | 2017-08-07 |
| SG11201701330PA (en) | 2017-04-27 |
| CL2017000558A1 (es) | 2017-11-10 |
| CN106687136A (zh) | 2017-05-17 |
| EP3193882A1 (en) | 2017-07-26 |
| KR20170036103A (ko) | 2017-03-31 |
| AU2015318257A1 (en) | 2017-02-16 |
| TWI599358B (zh) | 2017-09-21 |
| MX2017003414A (es) | 2017-06-19 |
| DOP2017000071A (es) | 2017-06-15 |
| EA201790305A1 (ru) | 2017-07-31 |
| BR112017003571A2 (pt) | 2017-12-19 |
| KR101871128B1 (ko) | 2018-06-25 |
| NZ728636A (en) | 2018-05-25 |
| AR101740A1 (es) | 2017-01-11 |
| CA2956835A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17029371A (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| EP3463464A4 (en) | ASSOCIATION TREATMENT | |
| GEAP202114450A (en) | Anti-tigit antibodies | |
| DK3240801T3 (da) | Kombinationstumorimmunterapi | |
| DK3209778T3 (da) | Kombination | |
| HUE054012T2 (hu) | Kombinációs terápia rák ellen | |
| DK3169292T3 (da) | Urinadsorberende tampon | |
| TWD174683S (zh) | 戒指 | |
| DK3171891T3 (da) | Fremgangsmåde | |
| DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
| DK3612624T3 (da) | Genterapi | |
| MA39483A (fr) | Agents thérapeutiques cibles | |
| EP3360010A4 (en) | BI PHOTONS WITH VOTABLE SOURCE | |
| DK3215607T3 (da) | Phagterapi | |
| IN2015DE00625A (es) | ||
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| IL262851A (en) | Combination prime: boost therapy | |
| ECSP17014972A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| MA40836A (fr) | Procédures de semi-synthèse | |
| MY167383A (en) | Disposable diaper | |
| DE112015001144A5 (de) | Therapievorrichtung | |
| GEAP201814327A (en) | Treatment regimen tiacumicin compound | |
| GT201400039S (es) | Diseño de bici-motocicleta |